Abstract:Objective To evaluate the efficacy and safety of Adefovir dipivoxil in the 52-week treatment of chronic hepatitis B in China.Methods We randomly assigned 480 patients with chronic hepatitis B who were positive for hepatitis B e antigen(HBeAg)in China.During the first 12-week period,480 patients were randomly to receive either 10 mg of adefovir dipivoxil(ADV)or placebo once daily in a 2:1 ratio and in the second period,all patients were accepted ADV for 18 weeks.In the last 12-week stage,all patients treated by ADV were randomly to receive either 10 mg of ADV or placebo in a 2:1 ratio and patients treated by placebo were accepted ADV.The primary end point was serum HBV DNA change during the treatment.The secondary endpoints were ALT normalization rate,HBeAg loss rate and HBeAg seroconversion rate.Results At week 12,median serum hepatitis B virus(HBV)DNA levels of group AAA(ADV-ADV-ADV)and group AAP(ADV-ADV-Placebo) were reduced 3.4 and 3.3 log copies per milliliter,significantly greater than group PAA(Placebo- ADV-ADV)of 0.1 log copies/ml reduction(P<0.05).At week 40,serum hepatitis B virus(HBV) DNA levels of all 3 groups were reduced 4.0～4.6 lg copies/ml.At week 52,median serum HBV DNA levels were reduced 5.0 and 4.5 log copies/ml in group PAA and AAA.Meanwhile,HBV DNA was reduced to level under detection in 30.3% and 28.4% patients of these 2 groups.However,HBV DNA level in group AAP rebound to baseline level and HBV DNA in only 0.8% patients(1/119)of this group was reduced to the level under detection.Alanine aminotransferase levels had normalized at week 52 in 69.2 percent and 78.6 percent of patients of groups PAA and AAA.Comparably.the ALT normalization rate reduced to 21.1%(23/109)at week 52 from 74.3%(81/109).HBeAg loss rate and HBeAg seroconversion rate at 52 week in group PAA were 200% and 17% compared with 13% and 8% in group AAA.However,the HBeAg loss rate and HBeAg seroconversion rate in group AAP were decreased from 14% and 11% at week 40 to 9% and 4% at week 52.No HBV polymerase mutations associated with resistance to ADV were identified.Only 5%～11% patients had at least one adverse event and most of which were mild to moderate.There were no significant differences in the changes in serum creatinine or serum phosphorus values compared with baseline level.Conclusions In Chinese patients with HBeAg-positive chronic hepatitis B,52 weeks of ADV treatment resulted in sig- nificant virologic,and biochemical improvement with good safety profile.No evidence of the emer- gence of adefoyir-resistant HBV polymerase mutations was found.

496 Efficacy and safety of 2 years adefovir dipivoxil (ADV) in chinese patients with HBeAg positive chronic hepatitis B (CHB)

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China

A Double-Blind Randomized Trial of Adefovir Dipivoxil in Chinese Subjects with HBeAg-positive Chronic Hepatitis B

A Randomized, Double-Blind, Multicenter Study of Adefovir Dipivoxil in Treating Patients with HBeAg-positive Chronic Hepatitis B

A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B]

Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B.

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.

[A Clinical Study of Adefovir Dipivoxil in Treating Lamivudine Refractory HBeAg-positive Chronic Hepatitis B].

A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study: Adefovir versus Entercavir for Chronic Hepatitis B.

Early Kidney Injury During Long-Term Adefovir Dipivoxil Therapy for Chronic Hepatitis B.

Comparison of the Antiviral Effects of Entecavir and Adefovir Dipivoxil in Chronic Hbv Infection: A Randomized Control Trial

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

Two Years Efficiency of Lamivudine and Adefovir Dipivoxil Combined Therapy in Chronic Hepatitis B Patients

The Clinical Efficacy of the Adefovir Dipivoxii in the Treatment of 36 Chronic Hepatitis B Patients with HBeAg-positive

Changes of HBV DNA titers and serum alanine aminotransferase level in chronic hepatitis B patients during adefovir dipivoxil treatment

LAM add-on ADV combination therapy or ETV monotherapy for CHB patients with suboptimal response to ADV.

Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy

Efficacy of 2years of Entecavir Plus Adefovir Therapy in Patients with Chronic Hepatitis B Who Had Failed on Prior Nucleos(t)ide Analog Treatment.

Compare with Safety and Efficacy of Entecavir and Adefovir Dipivoxil Combination Therapy and Tenofovir Disoproxil Fumarate Monotherapy for Chronic Hepatitis B Patient with Adefovir-Resistant.

The Study of Combined Lamivudine and Adefovir Therapy in HBeAg-positive Chronic Hepatitis B Patients with Poor Response to Adefovir Monotherapy